MET - MetLife, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$108.25
DETAILS
HIGH:
$111.00
LOW:
$103.00
MEDIAN:
$109.50
CONSENSUS:
$108.25
UPSIDE:
8.21%
AlphaVal
Deterministic, archetype-aware fair value
Banks, Insurers & Asset Managers
85% confidence
Primary model: P/Tangible Book × ROE Quality
Adjust Assumptions
11.9%
8.6%
Key Value Driver
ROTCE (11.9%) vs. cost of equity (8.6%)
Implied Market Multiple
2.24x
Plain-Language Summary
With ROTCE of 11.9% vs. 8.6% cost of equity, fair P/TBV is 1.73x on $44.69 tangible book, implying $89.10 per share. DDM cross-check: $47.37.
Analyst Consensus (External Reference)
Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.
Average Target (33 analysts)
$108.25
Analyst Range
$103.00 – $111.00
Divergence from AlphaVal
18%
Warnings
Traditional cash flow models don't work well for banks — lending activity distorts how much cash the business actually generates.
Common valuation shortcuts don't apply here — for banks, interest payments are a core business cost, not overhead.
Dividend-based valuation: $47.37 (47% below our primary estimate). Large gaps suggest the dividend may not fully reflect the company's value.
Key Risks
- Book value quality matters as much as level — check loan loss reserves
- Interest rate sensitivity creates non-linear earnings surprises
- Insurance reserving is actuarial, not financial — errors emerge slowly